MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues
Science Bulletin · 2026-06 · 71 (11) · 2916-2932
DOI: 10.1016/j.scib.2026.04.048 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Science Bulletin, 2026-06. Verfasst von Suki Ha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Healt…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Innovation and Technology Fund.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading chronic liver disease on a global scale. With its increasing incidence and advances in research technologies, our understanding of the mechanisms, non-invasive diagnostic strategies and therapeutic approaches for MASLD and its more advanced forms, including metabolic dysfunction-associated steatohepatitis (MASH) and hepatocellular carcinoma (HCC), has substantially expanded. This article reviews the pathophysiological mechanisms underlying MASLD and its transition to more severe forms, evolving from well-established mechanisms including insulin resistance, abnormalities in lipid metabolism and inflammation, to recently explored novel mechanisms, such as immune regulation, RNA modification and gut microbiome. Additionally, emerging biomarkers for diagnosis and prognosis, such as non-invasive serum markers and genetic variants are highlighted. This review evaluates contemporary therapeutic strategies, with particular emphasis on the recent FDA approval of resmetirom and semaglutide, alongside other pharmacological agents currently in phase 3 clinical trials. It also discusses innovative interventions aimed at improving the management of MASLD and MASLD-HCC, specifically in the context of gut modulation and enhancing the efficacy of immunotherapy. The necessity for strategies aimed at early detection and multifactorial treatment approaches is critical to address the rising burden of MASLD and its complications, with a call for further research into personalised medicine and innovative multidisciplinary therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University o…
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Di…
Förderung
- National Natural Science Foundation of China
- Innovation and Technology Fund
Zitieren
APA
Ha, S., Zhang, X., Li, L., & Yu, J. (2026). MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues. Science Bulletin, 71(11), 2916-2932. https://doi.org/10.1016/j.scib.2026.04.048
Vancouver
Ha S, Zhang X, Li L, Yu J. MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues. Science Bulletin. 2026;71(11):2916-2932. doi:10.1016/j.scib.2026.04.048
BibTeX
@article{Ha2026,
author = {Ha, Suki and Zhang, Xiang and Li, Lanjuan and Yu, Jun},
title = {MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues},
journal = {Science Bulletin},
year = {2026},
volume = {71},
number = {11},
pages = {2916--2932},
doi = {10.1016/j.scib.2026.04.048}
}
EUVIMED